Oncology and Hematology

Oncology and Hematology Clinical Practice

Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.

Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.

Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.

1011

LikeLikedUnlike

1-15 of 355

The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
CME/CE Virtual Event
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 29, 2026
12:00 PM - 01:00 PM EDT
1.00 credits
CME/CE In-Person & Virtual Event
Spotlight on B7-H3 ES-SCLC: Applying ADC Evidence in Real-World Practice
December 5, 2026
Scottsdale, Arizona
1.00 credits
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
MinuteCE®
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
- Komal Jhaveri, MD, FACP
0.50 program credits
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
MinuteCE®
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
- Virginia Kaklamani, MD, DSc
0.50 program credits
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
MinuteCE®
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
MinuteCE®
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
advertisement
MinuteCE®
Oral SERDs and PROTACs in ER+/HER2− mBC: Testing Smarter, Treating Better
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 credits 4 episodes
Secondary Stroke Prevention: Antithrombotic Strategies for Neurologists, Hematologists, and Cardiologists
CME/CE
Secondary Stroke Prevention: Antithrombotic Strategies for Neurologists, Hematologists, and Cardiologists
- Deborah Siegal, MD, MSc, FRCPC
- Geoffrey Barnes, MD, MSc
- Mike Sharma, MD, MSc, FRCPC
- Jeffrey Weitz, MD
1.00 credits
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
MinuteCE®
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
- Natalie S. Callander, MD
0.75 program credits
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
MinuteCE®
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 program credits
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
CME/CE
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
- Sagar Lonial, MD, FACP
1.00 credits
MinuteCE®
The Frontline Imperative: Integrating Anti-CD38–Based Regimens Into Multiple Myeloma Care in Community Practice
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 credits 4 episodes
advertisement
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
MinuteCE®
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
- Saad Z. Usmani, MD, MBA
0.75 program credits
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
MinuteCE®
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 program credits
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
CME/CE
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
- Amer Zeidan, MBBS
- Ghayas Issa, MD
0.50 credits